NEKTAR THERAPEUTICS Uncategorized Contracts & Agreements
40 Contracts & Agreements
- Letter Agreement dated as of September 6, 2023 by and between Bristol-Myers Squibb and Company and Nektar Therapeutics (Filed With SEC on November 8, 2023)
- Co-Development Agreement, dated as of February 1 (Filed With SEC on February 26, 2021)
- Description of Securities (Filed With SEC on February 28, 2020)
- Investor Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics (Filed With SEC on May 10, 2018)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- AMENDEDAND RESTATED COMPENSATIONPLAN FOR NON-EMPLOYEE DIRECTORS (Filed With SEC on December 14, 2009)
- LICENSEAGREEMENT byand between ASTRAZENECAAB and NEKTARTHERAPEUTICS DATE:September20, 2009 (Filed With SEC on November 5, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- Current assets (Filed With SEC on May 9, 2008)
- Current assets (Filed With SEC on May 9, 2008)
- NEKTAR THERAPEUTICS (Filed With SEC on March 1, 2007)
- EXHIBIT A EMPLOYEE AGREEMENT (Filed With SEC on January 9, 2007)
- [Nektar Letterhead] (Filed With SEC on March 16, 2006)
- [Nektar Therapeutics Letterhead] (Filed With SEC on March 8, 2006)
- NEKTAR THERAPEUTICS (Filed With SEC on March 21, 2005)
- THECORPORATEPLAN FOR RETIREMENTSM (PROFITSHARING/401(K) PLAN) A FIDELITYPROTOTYPE PLAN Non-StandardizedAdoption Agreement No. 001 For use With FidelityBasic Plan Document No. 02 (Filed With SEC on August 5, 2004)
- THE CORPORATEPLAN FOR RETIREMENTSM FIDELITY BASIC PLAN DOCUMENT NO. 02 2003 FMR Corp. All rights reserved. (Filed With SEC on August 5, 2004)
- RESALEREGISTRATION RIGHTS AGREEMENT (Filed With SEC on November 3, 2003)
- RESALEREGISTRATION RIGHTS AGREEMENT (Filed With SEC on October 10, 2003)
- EMPLOYEERELOCATION REPAYMENT AGREEMENT (Filed With SEC on May 13, 2003)
- NUMBER (Filed With SEC on January 23, 2003)
- CONFIDENTIAL (Filed With SEC on November 14, 2002)